Vaccine composition and uses thereof
AssigneeImugene Limited
InventorsNicholas Ede, Ursula Wiedermann, Joshua Tobias, Christoph Zielinski
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a vaccine composition for raising a humoral response to PD1, and uses thereof, for treating a cancer characterised by an involvement of PD1, wherein the vaccine composition comprises an effective amount of an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PD1.
Claims16
A method of treating a cancer, the method comprising administering to a human subject having a cancer characterized by an involvement of programmed cell death protein 1 (PD1) a vaccine composition comprising an effective amount of an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PD1,
- wherein the immunogen comprises a B cell epitope of PD1, wherein the B cell epitope of PD1 consists of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 9, 10, 14, 24, 28, 29, 42, 43, 49, and a combination of two or more of the foregoing, and wherein the amino acid sequence of the immunogen is not identical to a continuous stretch of at least 50 amino acid residues of PD1.
A vaccine composition for raising a humoral response to PD1, wherein the vaccine composition comprises an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PD1, wherein the immunogen comprises a B cell epitope of PD1, wherein the B cell epitope of PD1 consists of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 9, 10, 14, 24, 28, 29, 42, 43, and 49, and a combination of two or more of any of the foregoing, wherein the amino acid sequence of the immunogen is not identical to a continuous stretch of at least 50 amino acid residues of PD1, and wherein the vaccine composition further comprises an adjuvant.
Dependencies are inferred from the claim text.